abemaciclib
FDA Expands Indications for Verzenio in Patients With Breast Cancer
The FDA has expanded the indications for abemaciclib (Verzenio, Eli Lilly) in early and metastatic breast cancer, ...
MARCH 31, 2023
FDA Approves Verzenio for Early Breast Cancer
The FDA approved abemaciclib (Verzenio, Lilly) with endocrine therapy (tamoxifen or an aromatase inhibitor) for ...
OCTOBER 19, 2021
Abemaciclib Approved for Advanced HR-Positive/HER2-Negative Breast Cancer
With its FDA approval, abemaciclib (Verzenio, Lilly) has risen to the top of the cyclin-dependent kinase (CDK) 4/6 ...
OCTOBER 2, 2017
Abemaciclib Active in Early Breast Cancer
Results from a Phase II trial support further study of the CDK 4/6 inhibitor abemaciclib and anastrozole in ...
MARCH 17, 2017
Load more